Inhibitor of apoptosis proteins as therapeutic targets in bladder cancer
Abstract: Evasion from apoptosis is a hallmark of cancer. Inhibitor of apoptosis proteins (IAPs) contribute to this hallmark by suppressing the induction of cell death. IAPs were found to be overexpressed in cancerous tissues and to contribute to therapeutic resistance. The present review focuses on the IAP members cIAP1, cIAP2, XIAP, Survivin and Livin and their importance as potential therapeutic targets in bladder cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
Frontiers in oncology. - 13 (2023) , 1124600, ISSN: 2234-943X
- DOI
-
10.3389/fonc.2023.1124600
- URN
-
urn:nbn:de:bsz:25-freidok-2342355
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
25.03.2025, 1:48 PM CET
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Wolf, Philipp
- Universität
Time of origin
- 2023
Other Objects (12)
Evaluation of Inhibitors of Apoptosis Proteins as a therapeutic target in Gastrointestinal Stromal Tumors
Evaluation of Therapeutic Targets in Histological Subtypes of Bladder Cancer
Therapeutic kinase inhibitors
Therapeutic significance of ARID1A mutation in bladder cancer
Promising Novel Therapeutic Strategies for Cisplatin Resistant Bladder Cancer
Therapeutic targeting of signal transduction pathways in bladder cancer
The macrophage as therapeutic target
Ancistrocladinium A induces apoptosis in proteasome inhibitor-resistant multiple myeloma cells: a promising therapeutic agent candidate
Shifting the balance of mitochondrial apoptosis: therapeutic perspectives
Fibroblast growth factor receptor (FGFR) alterations in squamous differentiated bladder cancer - a putative therapeutic target for a small subgroup
Combining Oncolytic Virotherapy with Target Therapy in Bladder Cancer
Aspartic acid proteases as therapeutic targets
Evaluation of Inhibitors of Apoptosis Proteins as a therapeutic target in Gastrointestinal Stromal Tumors
Evaluation of Therapeutic Targets in Histological Subtypes of Bladder Cancer
Therapeutic kinase inhibitors
Therapeutic significance of ARID1A mutation in bladder cancer
Promising Novel Therapeutic Strategies for Cisplatin Resistant Bladder Cancer
Therapeutic targeting of signal transduction pathways in bladder cancer
The macrophage as therapeutic target
Ancistrocladinium A induces apoptosis in proteasome inhibitor-resistant multiple myeloma cells: a promising therapeutic agent candidate
Shifting the balance of mitochondrial apoptosis: therapeutic perspectives
Fibroblast growth factor receptor (FGFR) alterations in squamous differentiated bladder cancer - a putative therapeutic target for a small subgroup
Combining Oncolytic Virotherapy with Target Therapy in Bladder Cancer
Aspartic acid proteases as therapeutic targets
Evaluation of Inhibitors of Apoptosis Proteins as a therapeutic target in Gastrointestinal Stromal Tumors
Evaluation of Therapeutic Targets in Histological Subtypes of Bladder Cancer
Therapeutic kinase inhibitors
Therapeutic significance of ARID1A mutation in bladder cancer
Promising Novel Therapeutic Strategies for Cisplatin Resistant Bladder Cancer
Therapeutic targeting of signal transduction pathways in bladder cancer
The macrophage as therapeutic target
Ancistrocladinium A induces apoptosis in proteasome inhibitor-resistant multiple myeloma cells: a promising therapeutic agent candidate
Shifting the balance of mitochondrial apoptosis: therapeutic perspectives
Fibroblast growth factor receptor (FGFR) alterations in squamous differentiated bladder cancer - a putative therapeutic target for a small subgroup
Combining Oncolytic Virotherapy with Target Therapy in Bladder Cancer